At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARQT Arcutis Biotherapeutics Inc.
Post-Mkt 04-15 19:58:29 EDT
24.58
-0.51
-2.03%
盘后24.26
-0.32-1.30%
18:20 EDT
High25.33Low24.21Vol775.46K
Open25.09D1 Closing25.09Amplitude4.46%
Mkt Cap3.05BTradable Cap2.17BTotal Shares124.03M
T/O19.04MT/O Rate0.88%Tradable Shares88.24M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities
TIPRANKS  ·  04-14 04:55
Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities
Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next
Simply Wall St.  ·  04-07
Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next
Arcutis director Howard G. Welgus disposes of common shares worth $0.2 million
Reuters  ·  04-04
Arcutis director Howard G. Welgus disposes of common shares worth $0.2 million
Arcutis management to present at Needham Virtual Healthcare Conference fireside chat
Reuters  ·  04-01
Arcutis management to present at Needham Virtual Healthcare Conference fireside chat
How New Infant Atopic Dermatitis Data And sNDA Plans At Arcutis (ARQT) Have Changed Its Investment Story
Simply Wall St.  ·  03-30
How New Infant Atopic Dermatitis Data And sNDA Plans At Arcutis (ARQT) Have Changed Its Investment Story
Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
TIPRANKS  ·  03-29
Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
Arcutis says Phase 2 trial shows Zoryve cream improves infant atopic dermatitis
Reuters  ·  03-28
Arcutis says Phase 2 trial shows Zoryve cream improves infant atopic dermatitis
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness
Simply Wall St.  ·  03-19
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness
Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
TIPRANKS  ·  03-18
Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
Arcutis to present new ZORYVE trial data at American Academy of Dermatology annual meeting
Reuters  ·  03-18
Arcutis to present new ZORYVE trial data at American Academy of Dermatology annual meeting
Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream
TIPRANKS  ·  03-10
Arcutis Biotherapeutics announces publication on Phase 3 study of Zoryve cream
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data With Zoryve® (Roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
THOMSON REUTERS  ·  03-10
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data With Zoryve® (Roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
TIPRANKS  ·  03-10
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT)
TIPRANKS  ·  03-09
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT)
Press Release: Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Dow Jones  ·  03-05
Press Release: Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Arcutis (ARQT) Earnings Call Signals Scaled Growth
TIPRANKS  ·  03-05
Arcutis (ARQT) Earnings Call Signals Scaled Growth
Arcutis Biotherapeutics Director Keith R Leonard Disposes of Common Shares
Reuters  ·  03-05
Arcutis Biotherapeutics Director Keith R Leonard Disposes of Common Shares
Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
TIPRANKS  ·  03-03
Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Reuters  ·  03-03
BRIEF-Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Arcutis Begins Enrolling Phase 1a/1B Study Evaluating Arq-234, a Cd200r Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
THOMSON REUTERS  ·  03-03
Arcutis Begins Enrolling Phase 1a/1B Study Evaluating Arq-234, a Cd200r Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

Introduction

Company Name.
Arcutis Biotherapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Issue price:
--